The latter is often but not always seen in immunosuppressed patients
In a trial of WEGOVY injection in adult patients with type 2 diabetes and body mass index (BMI) greater than or equal to 27 kg/m2 for weight reduction (Study 3), hypoglycemia (defined as a plasma glucose less than 54 mg/dL) was reported in more patients treated with WEGOVY versus placebo [see Adverse Reactions (6.1)]
Upon activation, phosphorylated MLKL (p-MLKL) oligomerizes and translocates to the cell membrane, forming pores that disrupt electrochemical gradients, resulting in lytic cell rupture and the release of damage-associated molecular patterns (DAMPs), inflammatory cytokines and chemokines
This once-a-week injectable medicine has different dose options, typically starting with a 2.5 mg dosage and increasing to a 5 mg dosage after four weeks
Side effects are often minimized by starting low and increasing gradually
For weight loss, the appetite suppression is a game-changer